间充质干细胞移植治疗急性心肌梗死的安全性和有效性的荟萃分析

发布时间：2018-02-11 13:30

本文关键词： 急性心肌梗死间充质干细胞荟萃分析　出处：《临床心血管病杂志》2017年01期 　论文类型：期刊论文

【摘要】：目的:通过荟萃分析探讨间充质干细胞移植治疗急性心肌梗死的安全性和有效性。方法:检索Pubmed、Medline、Cochrane图书馆和Cochrane对照试验注册中心、中国生物医学文献服务系统数据库,应用RevMan 5.3软件进行定量分析。结果:8篇随机对照临床试验共410例纳入本荟萃分析,安全性方面移植组和对照组在全因死亡、移植相关事件、再发心肌梗死、致命性心律失常、免疫系统不良事件中的差异无统计学意义;有效性方面,移植组的左心室射血分数在3、6、12个月时比对照组分别增加9.65%(95%CI:0.89%~18.41%;P=0.03)、3.34%(95%CI:1.48%~5.21%;P=0.0004)、2.56%(95%CI:1.04%~4.09%;P=0.001),均有统计学意义,移植组和对照组在左心室收缩末期容积、左心室舒张末期容积方面的差异无统计学意义。结论:间充质干细胞移植治疗急性心肌梗死不增加主要临床不良事件的风险,在较长时间的随访中有提高左心室功能的作用。
[Abstract]:Objective: to investigate the safety and efficacy of mesenchymal stem cell transplantation in the treatment of acute myocardial infarction by meta-analysis. Results 410 cases of 8 randomized controlled clinical trials were included in this meta-analysis. In terms of safety, transplantation group and control group were involved in all-cause death, transplantation-related events, recurrent myocardial infarction and fatal arrhythmia. There was no significant difference in the adverse events of the immune system. In terms of effectiveness, the left ventricular ejection fraction (LVEF) in the transplantation group was increased by 9.65% 95 CI: 0.89% at 12 months compared with the control group at 12 months, respectively. There was a significant increase in the left ventricular ejection fraction in the transplantation group and in the control group at the end of left ventricular systolic volume, both in the transplantation group and in the control group, at the end of the left ventricular systolic volume. Conclusion: transplantation of mesenchymal stem cells does not increase the risk of major clinical adverse events in acute myocardial infarction.
【作者单位】：福建医科大学;厦门大学;厦门大学附属中山医院;
【分类号】：R542.22

【相似文献】